309 related articles for article (PubMed ID: 19496088)
21. [Modern technologies in diabetology. CSII (continuous subcutaneous insulin infusion) and CGM (continuous glucose monitoring) in clinical practice].
Olsovský J
Vnitr Lek; 2011 Nov; 57(11):919-22. PubMed ID: 22165697
[TBL] [Abstract][Full Text] [Related]
22. Needle detachment from the Sure-T infusion set in two young children with diabetes mellitus (DM) treated with continuous subcutaneous insulin infusion (CSII) and unexplained hyperglycaemia.
Massa G; Gys I; Eyndt AO; Wauben K; Vanoppen A
J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):237-9. PubMed ID: 25153227
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
Schernthaner G; Borkenstein M; Fink M; Mayr WR; Menzel J; Schober E
Diabetes Care; 1983; 6 Suppl 1():43-8. PubMed ID: 6343038
[TBL] [Abstract][Full Text] [Related]
24. [Current technics in the improvement of insulin treatment].
Spinas GA; Berger W
Ther Umsch; 1989 Oct; 46(10):715-21. PubMed ID: 2683184
[TBL] [Abstract][Full Text] [Related]
25. Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes.
Moghissi ES
Mt Sinai J Med; 2008 Dec; 75(6):558-66. PubMed ID: 19021195
[TBL] [Abstract][Full Text] [Related]
26. High antigenicity of intraperitoneal insulin infusion via implantable devices: preliminary rat studies.
Jeandidier N; Boullu S; Delatte E; Sapin R; Steibel J; Meyer P; Uhl C; Pinget M
Horm Metab Res; 2001 Jan; 33(1):34-8. PubMed ID: 11280713
[TBL] [Abstract][Full Text] [Related]
27. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.
Siebenhofer A; Jeitler K; Berghold A; Horvath K; Pieber TR
Diabet Med; 2009 Mar; 26(3):311-2; author reply 312-3. PubMed ID: 19317829
[No Abstract] [Full Text] [Related]
28. [Insulin antibody titres--observations on their course in patients with diabetes mellitus. A case report].
Grüneklee D; Takaishi T; Daweke H
Munch Med Wochenschr; 1970 Jul; 112(27):1287-91. PubMed ID: 4193069
[No Abstract] [Full Text] [Related]
29. Medical Grand Rounds. Open and closed loop insulin delivery systems in diabetes: current status.
Service FJ
Henry Ford Hosp Med J; 1982; 30(3):163-7. PubMed ID: 6761321
[No Abstract] [Full Text] [Related]
30. Continuous subcutaneous insulin usage in a patient with no gut.
Annamalai AK; Mankia S; Kandasamy N; Donald S; Adler AI
Diabet Med; 2010 Mar; 27(3):364-6. PubMed ID: 20536503
[No Abstract] [Full Text] [Related]
31. Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients.
Jeandidier N; Boullu S; Busch-Brafin MS; Chabrier G; Sapin R; Gasser F; Pinget M
Diabetes Care; 2002 Jan; 25(1):84-8. PubMed ID: 11772906
[TBL] [Abstract][Full Text] [Related]
32. Insulin resistance and new insulins.
Yue DK; Turtle JR
Aust Fam Physician; 1977 Mar; 6(3):286, 289. PubMed ID: 869782
[TBL] [Abstract][Full Text] [Related]
33. Insulin's 85th anniversary--An enduring medical miracle.
Heller S; Kozlovski P; Kurtzhals P
Diabetes Res Clin Pract; 2007 Nov; 78(2):149-58. PubMed ID: 17482306
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of unstable diabetes by continuous subcutaneous infusion of insulin].
Capani F; Consoli A; Guagnano T; Vitacolonna E; Sensi S
Boll Soc Ital Biol Sper; 1981 Jul; 57(13):1424-6. PubMed ID: 7284110
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy.
Jaeger C; Eckhard M; Brendel MD; Bretzel RG
Exp Clin Endocrinol Diabetes; 2004 Sep; 112(8):416-21. PubMed ID: 15372360
[TBL] [Abstract][Full Text] [Related]
36. Immunological responses to exogenous insulin.
Fineberg SE; Kawabata TT; Finco-Kent D; Fountaine RJ; Finch GL; Krasner AS
Endocr Rev; 2007 Oct; 28(6):625-52. PubMed ID: 17785428
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of anti-insulin-antibodies.
Andersen OO
Acta Endocrinol Suppl (Copenh); 1976; 205():231-40. PubMed ID: 1087092
[TBL] [Abstract][Full Text] [Related]
38. Diabetes and surgery.
Belcaro G; Cotellese R; Gargano E; Filippini A; Magrl M
Acta Chir Belg; 1982; 82(2):133-8. PubMed ID: 7041498
[TBL] [Abstract][Full Text] [Related]
39. [The treatment of diabetes mellitus using continuous subcutaneous infusion].
van Ballegooie E; Sluiter WJ; Reitsma WD; Doorenbos H
Ned Tijdschr Geneeskd; 1980 Nov; 124(48):2038-42. PubMed ID: 7003403
[No Abstract] [Full Text] [Related]
40. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices.
Jeandidier N; Boivin S; Sapin R; Rosart-Ortega F; Uring-Lambert B; Réville P; Pinget M
Diabetologia; 1995 May; 38(5):577-84. PubMed ID: 7489841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
